A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 20 mg and to evaluate the safety and tolerability of AZD0865.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A 4-week, Randomised, Double-blind, Multicentre, Dose-finding Phase IIb Study With AZD0865 25, 50, 75 mg and Esomeprazole 20 mg, Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification in Adult Subjects.|
- Time to sustained absence of patient-reported heartburn.
- The Quality of Life in Reflux and Dyspepsia (QOLRAD).
- Patient-reported symptoms.
- Investigator-reported symptoms.
- Population pharmacokinetics (PK). Area under the concentration-time curve (AUC) and the oral clearance calculated by dose/AUC (CL/F).
- pH monitoring.
- Safety (Adverse events, Laboratory variables, BP, pulse, ECG and physical examination).
|Study Start Date:||May 2004|
|Study Completion Date:||April 2005|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00206284
Show 202 Study Locations